INO-5150 Triggers Immune Responses, Delays Progression of Prostate Cancer That Returns, Trial Shows

INO-5150 Triggers Immune Responses, Delays Progression of Prostate Cancer That Returns, Trial Shows
The immunotherapy INO-5150 has shown promise as a treatment for prostate cancer that returns after surgery, according to a Phase 1b clinical trial. Inovio Pharmaceuticals' cancer vaccine generated immune responses in 60 percent of patients with recurrent prostate cancer and delayed the progression of the disease, researchers said. The company presented the findings at the European Society for Medical Oncology Congress in Madrid, Sept. 8-12. The poster session was titled "Safety and immunogenicity of a DNA-vaccine immunotherapy in men with biochemically (PSA) relapsed prostate cancer." Researchers said INO-5150 triggered immune-system T-cell responses against two proteins associated with prostate cancer in 60 percent of men whose disease had returned. The proteins, PSA and PSMA, are biomarkers of the cancer. The therapy also delayed the progression of the cancer, as assessed through PSA doubling time — the amount of time it takes for PSA levels to double. "Our study provides encouraging immunologic and clinical data that Inovio’s immunotherapy product can generate antigen-specific CD8+ killer T-cell responses in the blood and link such responses to PSA changes in prostate cancer patients," Dr. Neil Shore, a prostate cancer specialist at Urologic Associates of North Carolina, said in a press release. "Our results suggest that further ev
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *